Immunovia announced the successful completion of the discovery phase for the Company's next -generation test. The discovery study, which marks a key milestone in the development of Immunovia's next-generation test to detect early-stage pancreatic cancer, successfully found more than a dozen proteins circulating in the blood that identified pancreatic ductal adenocarcinoma (PDAC) stage I and stage II patients. The study is the most comprehensive pancreatic proteomics study done to date and utilized the Olink platform to explore nearly 3,000 protein biomarkers.

The new test is designed to work across all racial and ethnic groups without compromising accuracy, overcoming a key limitation of Immunovia's first-generation test, IMMray PanCan-d.